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Summary
Background Around two-thirds of patients with psoriasis do not adhere to topical
treatment. The Topical Treatment Optimization Programme (TTOP), a five-
element tool, includes guidance for the conversation between dermatologists/
nurses and patients, patient information material, telephone/e-mail helpdesks
and treatment reminders. It has been developed by patients and dermatologists to
help increase adherence to treatment in psoriasis.
Objectives To compare TTOP with standard of care (‘non-TTOP’) within a large
European investigator-initiated study, PSO-TOP (clinicaltrials.gov NCT01587755).
Methods Patients with mild-to-moderate psoriasis received calcipotriol/betametha-
sone dipropionate gel as standardized study medication and were randomized
1 : 1 to either TTOP or non-TTOP management. Study medication was applied
once daily for 8 weeks followed by ‘as needed’ application for an additional
56 weeks. Response was defined as a Physician’s Global Assessment (PGA) of
‘clear’ or ‘almost clear’.
Results In 1790 patients (full analysis set), response rates after 8 weeks (primary
objective) were significantly higher for TTOP (363%) than for non-TTOP
(313%, P = 00267). Better clinical outcome was accompanied by higher rates
of patients feeling well informed about their skin condition, treatment and other
factors related to adherence, but the Dermatology Life Quality Index was not sta-
tistically different. TTOP patients regarded the structured one-to-one conversa-
tions with their dermatologist/nurse as the most important element of TTOP.
Conclusions Patients randomized to the TTOP intervention had a better clinical
response than patients receiving standard of care. Improved communication
between the healthcare provider and patient might be an important element in
increasing adherence to topical therapy in psoriasis.
© 2017 The Authors. British Journal of Dermatology
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What’s already known about this topic?
• Adherence rates in chronically ill patients, particularly those with psoriasis, are gen-
erally low.
• Poor adherence is linked to worse clinical outcomes and reduced quality of life, in
addition to increased direct and indirect costs.
• Interventions are needed to improve adherence in patients with psoriasis, which
should be multifaceted and tailored to the patient’s individual needs so that these
interventions are suitable for long-term use.
What does this study add?
• The Topical Treatment Optimization Programme (TTOP) was designed based on
input from experts and patients and comprises structured guidance for one-to-one
conversations between dermatologist/nurse and patients, patient information
materials, telephone/e-mail helpdesks and treatment reminders.
• Patients randomized to TTOP had a significantly better clinical outcome than
patients receiving standard of care, despite using less study medication.
• Improved communication between the dermatologist/nurse and patient might be
important for increasing adherence to topical therapy in psoriasis.
The World Health Organization defines adherence to long-term
therapy in chronic diseases as ‘the extent to which a person’s
behaviour. . . corresponds with agreed recommendations from
a healthcare provider’.1 Adherence, therefore, differs from
compliance in that it requires the patient’s agreement. Adher-
ence rates in chronically ill patients, particularly those with
psoriasis, are generally low. In an outpatient study where pre-
scriptions for initial treatments with a new medication were
tracked, patients with psoriasis were the least adherent group
assessed, with only 50% redeeming their prescriptions.2 Adher-
ence rates to topical therapies in psoriasis are around 50–
70%,3–5 although rates can be as low as 40% for topical corti-
costeroids and in patients with severe disease.4,6 Poor adher-
ence is linked to worse clinical outcomes and reduced quality
of life, in addition to increased direct and indirect costs.7–9
Interventions are clearly needed to improve adherence to
treatment in psoriasis; these interventions should be multi-
faceted and tailored to the patient’s individual needs so that
they are suitable for long-term use.4 The factors impacting on
adherence can be grouped into three main categories, i.e. dis-
ease-, patient- and treatment-related factors. Treatment-related
factors include lack of efficacy and side-effects4,6 and, for topi-
cal therapies, low cosmetic acceptability, as patients prefer less
messy/sticky medication that is quick and easy to apply.6,9,10
As some of these factors cannot easily be changed (e.g. educa-
tional status of the patient), the focus should be on those factors
that can be influenced. For example, effective communication
between healthcare professionals and the patient plays a signifi-
cant role in adherence; in some diseases > 40% of patients
misunderstand, forget or simply ignore the advice of their
healthcare professional.11 The Topical Treatment Optimization
Programme (TTOP) was designed based on input from experts
and patients.12 TTOP comprises structured guidance for one-to-
one conversations between the dermatologist/nurse and
patients, patient information materials, telephone/e-mail help-
desks and treatment reminders for the patients. To evaluate
whether this tool could improve adherence, TTOP was assessed
in the large, investigator-initiated, long-term PSO-TOP study,
in which all patients received the same topical treatment but
were randomized to either standard of care (non-TTOP arm) or
management with the TTOP programme. Fixed combination
calcipotriol (Cal) 50 lg and betamethasone dipropionate (BD)
05 mg gel was selected as topical therapy based on its favour-
able patient satisfaction.9,13
Patients and methods
Patients
Eligible patients were men and women aged ≥ 18 years. All
patients were required to have active, mild-to-moderate pla-
que psoriasis with a Physician’s Global Assessment (PGA) of
disease severity of ≥ 2 and an affected body surface area
(BSA) of ≤ 10%. Each patient was required to have been
receiving topical treatment for at least 8 weeks prior to enrol-
ment and be naive to treatment with Cal/BD gel. The main
exclusion criteria were systemic treatment with biological
therapies or phototherapy during a given period prior to study
inclusion; severe renal or hepatic insufficiency; known hyper-
calcaemia; erythrodermic, exfoliative, pustular or guttate psori-
asis or facial or genital psoriasis; pregnancy or breastfeeding;
hypersensitivity to the active substances or to the excipients of
the study medication or fulfilment of at least one contraindica-
tion according to the study medications summary of product
characteristics (SmPC);14 suspected noncompliance and/or
current participation in another clinical trial.
© 2017 The Authors. British Journal of Dermatology
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This study was conducted in accordance with the Declara-
tion of Helsinki. An independent ethics committee and the
competent authority reviewed and approved the study. All
patients provided written informed consent (Data S1; see Sup-
porting Information).
Study design
PSO-TOP was a phase IV, 64-week, randomized controlled
study (EudraCT number 2011-001697-26). It was an investi-
gator-led (K.R.) study, designed, developed and conducted by
dermatology experts from Denmark, France, Germany, Italy,
the Netherlands, Spain, Sweden and the U.K., with additional
input from patient focus-group interviews.12 During the first
8 weeks, all patients applied Cal/BD gel once daily, then on
an ‘as needed’ basis in the following 56 weeks as per the
SmPC.14 At baseline, patients were randomly assigned 1 : 1 to
either the TTOP or non-TTOP intervention.12 An electronic
randomization list was generated by an independent third
party using the software RandList 1.2, and was stored in the
electronic case report form so that a randomization number
was automatically assigned in ascending order as soon as the
investigator confirmed the randomization of the patient. The
seven-digit randomization number was a combination of the
letter R (one digit), the combined site number (four digits;
comprising the country number and the site number – two
digits each) and the patient number (two digits).
TTOP contains the following five elements (Data S2–S6; see
Supporting Information):
1. Visit checklist with instructions for a one-to-one conver-
sation between dermatologist and patient
2. Visit checklist with instructions for a one-to-one conver-
sation between nurse and patient
3. Patient information material (the ‘TTOP Patient Brochure’)
4. Telephone and e-mail helpdesk for patients
5. Treatment reminders, where the nurse contacted the
patient at a given time.
Participating investigators and nurses from each study site
were carefully trained for the TTOP intervention by means of
a specific TTOP training programme, which included commu-
nication exercises and written background and instruction
materials (the ‘PSO-TOP Manual’). Study teams were asked to
have the same personnel managing patients longitudinally to
minimize inter-rater variability.
Objectives and assessments
The primary objective was to demonstrate a difference in
treatment responses to study medication in the TTOP and
non-TTOP arms. The primary efficacy end point was PGA
response after 8 weeks of treatment, with a responder having
a PGA of 0 (clear) or 1 (almost clear). Visits were planned at
weeks 4 and 8 ( 3-day and  7-day window at each visit,
respectively), then every 8 weeks during the ‘as needed’ per-
iod up to week 64. PGA and affected BSA were assessed at all
visits.15,16 Patient-reported outcomes – Patient’s self Global
Assessment (PsGA),12 Dermatology Life Quality Index
(DLQI)17 and the Topical Therapy Adherence Questionnaire
(TTAQ)18 – were collected at baseline, weeks 8, 40 and 64
(Data S1; see Supporting Information). At weeks 8 and 64,
patients randomized to the TTOP arm were asked to rank the
five TTOP elements from one (most important) to five (least
important). From baseline to week 8, treatment compliance
was assessed by measuring the patient-reported number of
days of Cal/BD gel application, while the extent of exposure
was measured by weighing the returned study medication for
all patients. The time required for consultations between the
patient and dermatologist/nurse were recorded at each visit.
Adverse events (AEs) were monitored throughout the study.
Statistical analysis
For the sample size calculation, it was assumed that the PGA
responder rate at week 8 would be around 40% in the non-
TTOP arm and 47% in the TTOP arm. To be able to show this
absolute difference of 7% with a type I error rate of 5% and a
power of 80%, and taking uneven distribution of patients
among the participating countries (depending on their size)
into account, a sample size of 1630 patients (815 per study
arm) was calculated. This analysis was originally based on the
full analysis set (FAS; all patients with any postrandomization
data) without imputation of missing values (i.e. as observed);
considering a 20% dropout rate, the target enrolment was
planned to be 1956 patients. However, owing to a lower-than-
expected dropout rate, the target number of 815 patients per
arm was achieved with a lower overall number of enrolled
patients (Fig. 1). As primary end point analyses of clinical trials
in psoriasis are usually performed using a more conservative
approach,19–21 in this paper we show the primary end point
analysis and all main long-term efficacy outcomes based on the
FAS with imputation of all patients with missing values as non-
responders (nonresponder analysis). Based on this method, the
number of enrolled patients (n = 893 in the TTOP and
n = 897 in the non-TTOP arm, respectively) allowed detection
of a 7% response difference between the arms with a power of
83% and detection of a 5% difference with a power of 58%.
Efficacy analyses were conducted on the FAS, while safety
analyses were performed in all randomized patients who
received the study drug. The primary study objective was
tested statistically in a hierarchical order. A two-sided
Cochran–Mantel–Haenszel test (continuity corrected) was used
to test for the overall effect (data from all countries) at
a = 5%. In case of significance (P ≤ 005), a Breslow–Day test
of homogeneity within countries was used at a = 5%. Two-
sided v2-tests (5% significance level) were performed by visit
and country to test the null hypothesis that the PGA responder
rate did not differ between treatment arms for weeks 16–64.
For exploratory reasons, the influence of possible prognostic
factors on PGA responder rate at week 8 was assessed using a
logistic regression model with the study arm, country and sex
as factors, and months since psoriasis diagnosis, age and
© 2017 The Authors. British Journal of Dermatology
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baseline Psoriasis Area and Severity Index score as covariates.
To compare mean PGA, PsGA and BSA from weeks 8 to 64
between the two study arms, Wilcoxon rank-sum tests (5%
significance level) were performed. Correlations between PGA
and DLQI and PGA and PsGA were calculated, and Spearman’s
rank correlation coefficient is provided.
Results
Patients
Between 24 February 2012 and 25 June 2014, 1852
patients were screened and 1803 were randomized to either
TTOP or non-TTOP (Fig. 1); a total of 13 patients were
excluded from the FAS and 1246 patients completed the
study.
Overall, patient demographics and characteristics were com-
parable between TTOP and non-TTOP arms (Table 1).
Use of study medication
From baseline to week 8 (i.e. 56  7 days), the mean  SD
number of days where Cal/BD gel was applied was
535  99 in the TTOP arm and 535  102 in the non-
TTOP arm. Patients randomized to non-TTOP had a consis-
tently higher mean use of study medication per percentage of
Randomized
n = 1803
FAS
n = 1790
TTOP
n = 893
Non-TTOP
n = 897
Week 8
n = 838c
Week 8
n = 818c
Screened
n = 1852
Screen failures
n = 49
Excluded from FASa
n = 13
Discontinued, n = 55
Lack of efficacy, n = 9
Consent withdrawal, n = 11
Lost to follow-up, n = 12
Other,b n = 23
Discontinued, n = 79
Lack of efficacy, n = 12
Consent withdrawal, n = 14
Lost to follow-up, n = 26
Other,b n = 27
Week 64
n = 636
Week 64
n = 610
Discontinued, n = 202
Lack of efficacy, n = 69
Consent withdrawal, n = 38
Lost to follow-up, n = 36
Other,b n = 59
Discontinued, n = 208
Lack of efficacy, n = 71
Consent withdrawal, n = 31
Lost to follow-up, n = 52
Other,b n = 54
Fig 1. Patient disposition. TTOP, Topical Treatment Optimization Programme. aNo informed consent (n = 8); data issues at investigational site
(n = 5). b’Other’ includes adverse events/serious adverse events, major protocol deviation, pregnancy or unspecified. cThe primary end point
analysis at week 8 was based on the full analysis set (FAS) using nonresponder imputation.
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affected BSA than patients in the TTOP arm (Table 2),
although the magnitude of the SDs suggests considerable vari-
ation in both arms.
Efficacy
The primary efficacy end point was fulfilled as 363% of TTOP
patients and 313% of non-TTOP patients had a PGA of 0 (clear)
or 1 (almost clear) at week 8 (P = 00267; Fig. 2). There was
no difference in responder rates between countries
(P = 0775), and the treatment effect at week 8 remained sig-
nificant after adjusting for potential confounding factors, such
as age, sex, disease duration and baseline severity (P = 00399).
From week 8 onwards, the numerical differences between the
TTOP and non-TTOP arms were maintained to week 64; statisti-
cally significant differences were noted at weeks 4, 8, 24, 32
and 48 (Fig. 2). The mean PGA of TTOP and non-TTOP patients
over weeks 8–64 was significantly different (P = 00343). The
mean BSA affected from baseline to week 64 decreased from
51 to 24 in the TTOP arm and from 50 to 27 in the non-
TTOP arm, with no statistically significant difference between
arms (P = 01196). In both arms of the study, mean PsGA val-
ues decreased from baseline to week 64 (TTOP 32  10 to
18  13; non-TTOP 31  10 to 19  12); there were no
statistically significant differences between arms. The correlation
between PsGA and PGA was moderate at baseline in both arms
(056, P < 0001 for both; Spearman’s rank correlation). At
week 64, the correlation increased to 085 in the TTOP arm and
082 in the non-TTOP arm (P < 0001 for both).
Patient-reported outcomes
Dermatology Life Quality Index
Mean baseline DLQI scores were similar in the TTOP
(52  47) and non-TTOP (50  45) arms (665% and
667% had a baseline DLQI of ≤ 5, respectively; while 188%
and 215% had a baseline DLQI of 0/1, respectively). The
mean decrease in DLQI from baseline to week 8 (decrease of
26  37 for TTOP; decrease of 22  34 for non-TTOP)
and to week 64 (24  41 for TTOP; 22  38 for non-
TTOP) was similar across arms. When patients who had a
DLQI of ≤ 5 were evaluated, the proportions in the TTOP and
non-TTOP arms were 815% and 773% at week 8, and
601% and 584% at week 64, respectively. The proportion of
patients achieving a DLQI of 0/1 in the TTOP and non-TTOP
arms was 479% and 441% at week 8, and 399% and 357%
at week 64, respectively.
Topical Therapy Adherence Questionnaire
It is not known whether the DLQI is a suitable tool to assess
adherence-relevant factors in the topical therapy of psoriasis.
Therefore, we additionally used the TTAQ, a patient question-
naire more specifically designed to address patient confidence
and treatment satisfaction, in addition to other parameters
known to influence adherence.18 For the statements related to
patient empowerment and adherence there was a significant
difference between TTOP and non-TTOP patients at week 8.
This indicates that TTOP positively influenced these factors
Table 1 Patient demographics and baseline characteristics (full
analysis set)
TTOP arm
(n = 893)
Non-TTOP arm
(n = 897)
Men 509 (570) 521 (581)
Age (years) 509  150 510  154
BMI (kg m2) 272  48 275  50
Duration of psoriasis (months)a 2158  1783 2082  1736
PASI 45  22 45  22
PGA
Mild 312 (349) 287 (320)
Mild-to-moderate 349 (391) 384 (428)
Moderate 192 (215) 188 (210)
Moderate-to-severe 35 (39) 35 (39)
Severe 5 (06) 3 (03)
BSA (%) 51  27 50  26
Patients with
Nail involvement 248 (275) 250 (279)
Psoriatic arthritis 76 (85) 74 (82)
Obesity 147 (165) 174 (194)
(Essential) hypertension 172 (193) 180 (201)
Patients with previous
systemic therapy
6 (07) 7 (08)
Patients with previous
phototherapy
5 (06) 3 (03)
Patients with previous
topical therapy
Corticosteroids 328 (367) 278 (310)
Vitamin D only 126 (141) 127 (142)
Combination 185 (207) 184 (205)
Other 35 (39) 36 (40)
Data are presented as mean  SD or n (%). BMI, body mass
index; BSA, body surface area; PASI, Psoriasis Area and Severity
Index; PGA, Physician’s Global Assessment of disease severity;
TTOP, Topical Treatment Optimization Programme. aDuration of
psoriasis could not be calculated for one patient in the TTOP
arm.
Table 2 Consumption of study medication (gram per interval) per
percentage of body surface area affected (full analysis set)
TTOP arm Non-TTOP arm
Baseline to week 4 73  99 (865) 80  95 (860)
Week 4–8 70  73 (817) 78  97 (807)
Week 8–16 107  117 (794) 120  178 (766)
Week 16–24 105  125 (752) 116  136 (716)
Week 24–32 104  120 (701) 116  173 (682)
Week 32–40 104  123 (655) 115  150 (645)
Week 40–48 95  111 (617) 110  140 (601)
Week 48–56 98  112 (606) 113  156 (589)
Week 56–64 95  107 (580) 113  157 (563)
Data are mean  SD (n). TTOP, Topical Treatment Optimization
Programme.
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published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2017) 177, pp197–205
Results of the 64-week randomized PSO-TOP study, K. Reich et al. 201
beyond the self-assessment of disease severity, which was
rated similarly in both groups (Table 3).
Assessment of Topical Treatment Optimization
Programme elements
The patients’ ranking of TTOP elements was similar at weeks
8 and 64, with one-to-one conversations with the dermatolo-
gist/nurse being of greatest importance at both time points
(Table 4). Telephone/e-mail helpdesk and reminder calls were
consistently regarded as being of least importance.
The time required for consultations decreased from baseline
to week 64 in both the TTOP (dermatologist 335  139 min
to 180  88 min; nurse 311  132 min to
146  83 min) and non-TTOP arms (dermatologist
252  129 min to 92  53 min; nurse 189  112 min
to 81  52 min). Visits for TTOP patients generally lasted
around 9–10 min longer than non-TTOP visits.
Safety and tolerability
Overall, 466% of the patients reported at least one AE (498%
of TTOP patients and 434% of non-TTOP patients; Table 5).
The frequency of patients with serious AEs was 68% in the
TTOP arm and 49% in the non-TTOP arm. One male patient
died during week 8 (TTOP arm), but neither the investigator
nor study sponsor considered the event to be related to the
study drug; the patient had a history of hypertension, hyper-
cholesterolaemia and obesity.
Drug-related AEs were reported in 45% of patients in the
TTOP arm and 37% in the non-TTOP arm; the most common
were pruritus and application-site pain (Table 5). Of the
drug-related AEs, four were severe (pruritus, skin irritation,
guttate psoriasis and drug intolerance). In addition, one AE of
moderate severity fulfilled the criteria for seriousness. A 23-
year-old woman experienced Quincke oedema and was
hospitalized overnight, receiving intravenous treatment with
prednisolone and dimetindene; she recovered fully. The inves-
tigator and sponsor classified the AE as possibly related to the
study drug.
40
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266/653
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308/659
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241/632
(38·1%) 
287/643
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261/616
(42·4%) 
302/636
(47·5%)
273/610
(44·8%)
Fig 2. Physician’s Global Assessment (PGA)
responder rates by study arm from week 4 to
week 64. The numbers shown in the figure
are based on the full analysis set using
nonresponder imputation. *P < 005;
**P < 001 vs. non-TTOP. aFor comparison,
the numbers shown below the x-axis given as
n/N (%) represent an ‘as observed’ analysis,
where n = number of patients reaching a PGA
response; N = number of patients with a PGA
value and % = PGA response rate based on
number of patients with PGA value. TTOP,
Topical Treatment Optimization Programme.
Table 3 Selected Topical Therapy Adherence Questionnaire (TTAQ)
statements – proportion of patients who strongly agreed (week 8)
TTAQ Response
TTOP arm
(n = 893)
Non-TTOP
arm
(n = 897)
A. ‘I am satisfied with the
efficacy of the
treatment’
Strongly
agree
413 (462) 358 (399)
B. ‘I am more confident
as a result of the
treatment’
Strongly
agree
412 (461) 328 (366)
C. ‘I feel well informed
about my skin
condition’
Strongly
agree
660 (739) 537 (599)
D. ‘My doctor has taken
enough time to
explain the
condition to me’
Strongly
agree
674 (755) 565 (630)
E. ‘I have understood how
to implement the
treatment to ensure that
I can easily handle
my condition’
Strongly
agree
667 (747) 576 (642)
Data are n (%). TTOP, Topical Treatment Optimization
Programme. Patients could rate each statement as ‘strongly dis-
agree’, ‘disagree’, ‘agree’ and ‘strongly agree’. Overall answers
to the above questions were statistically different between the
two groups (Wilcoxon rank-sum test with Bonferroni correction
for multiple comparison, P = 001). Based on Fisher’s exact test,
the responses to statements B, C, D and E were significantly dif-
ferent (P = 0001, P < 0001, P < 0001 and P < 0001, respec-
tively), but were not significantly different for statement A
(P = 0033).
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Discussion
There is substantial evidence highlighting that adherence rates
are low in psoriasis,4,9,10 which can lead to poor efficacy and
wasted healthcare resources.9,22,23 However, to the best of our
knowledge, there have not been any large, high-quality stud-
ies that document improved outcomes as a consequence of
the implementation of adherence strategies. TTOP was devel-
oped to provide tools that may help to improve adherence in
daily practice. Specifically, the TTOP intervention aimed to
augment the quantity/quality of information provided to the
patient and improve the relationship with the healthcare pro-
vider,12 as these factors are known to impact on adherence.3,4
It was thought that this patient-centric approach would help
patients feel more empowered in the treatment of their psoria-
sis, which would ultimately result in optimized outcomes. The
value of the TTOP intervention was tested against standard of
care in a large randomized 64-week study (PSO-TOP). To
avoid confounding by different topical treatments and formu-
lations, Cal/BD gel was used in all patients. According to the
study concept, the main outcomes included assessment of the
objective clinical response (i.e. PGA) and a patient question-
naire related to relevant factors involved in empowerment and
adherence (i.e. TTAQ).
After 8 weeks of therapy significantly more patients
achieved a PGA of ‘clear’ or ‘almost clear’ in the TTOP arm
than those in the non-TTOP arm (363% vs. 313%,
P = 00267); this superiority was maintained across countries
and when different disease- and patient-related factors were
included. The PGA response rate of ≥ 30% demonstrates that
Cal/BD gel is effective for treating psoriasis, even in patients
who had previously failed topical treatment. The data align
with previous Cal/BD gel studies,24,25 underlining the robust-
ness of the results collected in PSO-TOP. Significant differences
between the TTOP arm and the non-TTOP arm were observed
as early as 4 weeks, and at different time points during the ‘as
needed’ period. Mean PGA over the ‘as needed’ period was
also significantly higher for the TTOP arm than for the non-
TTOP arm, providing further support for a longer-term supe-
riority of the TTOP approach.
At all time points, mean overall and BSA-calculated use of
Cal/BD gel was higher in the non-TTOP arm than in the
TTOP arm, which is notable given that TTOP patients had a
significantly better clinical outcome based on PGA-defined
responder rates. We can speculate that because TTOP patients
were trained in the correct application and use of Cal/BD gel
at their first visit, with additional training at week 4 if neces-
sary, they used the medication in a more considered way,
applying it more accurately to the affected plaques and avoid-
ing excessive use. In line with this assumption, at week 8, sig-
nificantly more patients in the TTOP than in the non-TTOP
arm expressed that they understood the treatment.
As assessed by the TTAQ, the improved PGA response rate
at week 8 in the TTOP arm was accompanied by more
patients being confident as a result of the treatment, feeling
informed about the disease and stating that their doctor had
taken enough time to explain the condition, which are all
parameters that are likely to have an impact on adherence.
However, the changes in the DLQI and the self-assessment of
global disease severity (PsGA) were not significantly different
between the arms, although both clearly indicated
Table 4 Ranking of importance of Topical Treatment Optimization
Programme (TTOP) elements by patients randomized to the TTOP
arm at week 8 and week 64 (full analysis set)
TTOP element
Mean week-8
score (median)
Mean week-64
score (median)
Overall
ranking
One-to-one
conversation
with dermatologist
16 (10) 15 (10) 1
One-to-one
conversation
with nurse
21 (20) 20 (20) 2
Patient information
material
33 (30) 35 (30) 3
Telephone/e-mail
helpdesk
38 (40) 39 (40) 4
Reminders for using
treatment
40 (40) 40 (40) 5
Table 5 Adverse drug reactions
Adverse reaction
TTOP arm
(n = 891)
Non-TTOP
arm
(n = 897)
Total
(n = 1788)
Any AE 444 (498) 389 (434) 833 (466)
Any drug-related AE 40 (45) 33 (37) 73 (41)
Any serious AE 61 (68) 44 (49) 105 (59)
Any drug-related
serious AE
0 (00) 1 (01) 1 (01)
Common AEsa
Nasopharyngitis 72 (81) 66 (74) 138 (77)
Influenza 27 (30) 29 (32) 56 (31)
Upper respiratory
tract infection
19 (21) 17 (19) 36 (20)
Lower respiratory
tract infection
14 (16) 20 (22) 34 (19)
Worsening psoriasis 22 (25) 15 (17) 37 (21)
Headache 18 (20) 13 (14) 31 (17)
Diarrhoea 22 (25) 12 (13) 34 (19)
Back pain 33 (37) 24 (27) 57 (32)
Arthralgia 19 (21) 21 (23) 40 (22)
Common drug-related AEsb
Pruritus 4 (04) 6 (07) 10 (06)
Application-site pain 6 (07) 4 (04) 10 (06)
Worsening psoriasis 5 (06) 1 (01) 6 (03)
Erythema 0 (00) 5 (06) 5 (03)
Application-site
irritation
3 (03) 2 (02) 5 (03)
Data are provided as n (%). TTOP, Topical Treatment Optimiza-
tion Programme. aAdverse events (AEs) occurring in at least 2%
of patients in either treatment arm. bDrug-related AEs occurring
in at least five patients overall.
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improvement from baseline.26 This may be because the
observed difference in the PGA response rate was relatively
small and/or suggest a limited suitability of the DLQI to
address adherence factors specifically. This also reflects a num-
ber of potential limitations linked to the approach of testing
adherence strategies in a clinical trial such as PSO-TOP; in par-
ticular, the controlled setting including a preselection of
patients, in this case patients who had already failed previous
topical therapy; a structured visit scheme and the use of a
standardized high-quality treatment, all of which are necessary
to limit confounding; the increased awareness of physicians
and patients owing to participation in a clinical trial; and the
fact that most sites could not provide two separate investiga-
tional teams for TTOP and non-TTOP arms, thereby limiting
discrimination between the two strategies. All of these limita-
tions will have an impact on the factors that may lead to non-
adherence in a ‘real-world’ setting and/or potentially
minimize the likelihood of being able to differentiate between
the TTOP and non-TTOP intervention.
Our positive finding demonstrates that measures against
nonadherence are useful and can be tested and validated in
clinical trials. In this regard, the analyses of the ranking of
TTOP elements should be informative for future programmes
aimed at optimizing adherence. An improved quality of life
is a desirable treatment goal that could not be documented
in this study, but the TTAQ findings clearly indicate that
patients recognize the value of TTOP. This is particularly
true for the communication with a healthcare professional;
of the five TTOP elements, patients ranked the one-to-one
conversations with the dermatologist and nurse as being of
the highest importance. Information material, helpdesks and
reminder calls were not as relevant. As one might expect
from the design of the TTOP tool, its application led to
longer consultations (on average 9–10 min longer in the
TTOP than the non-TTOP arm). While this extra time may
be reduced in the future by the development of more effec-
tive communication strategies, it may have to be accepted
that better objective clinical outcomes and higher patient sat-
isfaction levels, in the case of a chronic illness such as psori-
asis, can only be achieved if dermatologists and nurses
invest more time communicating with and training their
patients.
Overall, Cal/BD gel was well tolerated in both treatment
arms. The type and frequency of adverse reactions were com-
parable with those listed in the fixed combination Cal/BD
SmPC and reported in a pooled safety analysis.14,27 There was
one report of a serious adverse reaction (Quincke oedema),
which is a rare but known adverse reaction to Cal.
In conclusion, the PSO-TOP study provides evidence that
optimized management of patients with psoriasis, based on
the five-element TTOP tool, can improve clinical outcome
compared with standardized topical therapy and positively
influences patient attitudes related to empowerment and
adherence as assessed by a novel questionnaire (TTAQ). Of
the elements contained in TTOP, patients rated the structured
one-to-one communication with dermatologists and nurses to
be the most important. The TTOP-optimized patient manage-
ment was associated with lower overall medication use than
standard of care, suggesting that TTOP might lead to better
adherence to topical medication. Overall, this study
demonstrates that interventions beyond the treatment itself
can influence treatment outcome and encourages further
research on treatment-independent measures to overcome
nonadherence.
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